Skip to main content
OpenTrials
Completed

NCT Number: NCT06168500

Narrow Implants Vs Standard Implants With Simultaneous GBR

NDI represent an advisable treatment option when the mesio-distal space is compromised. In a recent retrospective study with a follow-up of 8 years in which they wanted to evaluate the long-term survival, complications, peri-implant conditions, marginal bone loss, and patient satisfaction of fixed dental prostheses supported by NDI in the posterior area. They observe a survival rate of 97% and absence of prosthetic complications after the study period time. More recently, Souza et al. performed a prospective randomized split mouth study with 3 years follow-up with the aim of comparing marginal bone level, implant survival and success rates and prosthesis success rates of NDI and SDI placed in the posterior area of the mandible to support single prosthesis. They observed an implant survival rate of 100% for both groups at 1 and 3 years. The prosthesis success rate at 1 and 3 years was of 95.4% and 100%, respectively.

NDI present a high survival rate on the evaluated studies. Therefore, the aim of the first study is to compare the patient related outcomes, implants and prostheses success and survival rates of pure titanium NDI versus SDI with simultaneous bone regeneration in narrow alveolar ridges at posterior areas of the maxilla and the mandible.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Narrow Implant Bone Regeneration Dental Implant

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitat Internacional de Catalunya

Sant Cugat del Vallès, Barcelona, 08195, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients:

  • 18 years old
  • Healthy periodontal status (absence of generalized probing pocket depth (PPD) <4mm)
  • Oral hygiene levels (FMPS <20 and FMBS <20)

Site:

  • Ridge width of >5mm and <6.5mm and minimum bone height of 10mm prior evaluation on a CBCT scan
  • Presence of antagonistic natural tooth or fixed prosthetic restoration
  • Presence of adjacent teeth
  • One maxillary or mandibular premolars
  • Minimum of 3mm of keratinized tissue over the bone crest (20)
  • Bone regeneration within the limits of the prosthetic restoration.

Implants:

  • Unitary prosthesis
  • Screwed retained restorations

Exclusion criteria

Patients

  • Presence of active chronic or aggressive periodontal disease
  • Presence of systemic disease which contraindicate surgery (patients with an ASA ≥ 3)
  • Drugs or medications which may alter the results (chronic intake of analgesic medication)
  • Smokers (>10cig/day)
  • Pregnant women
  • History of head and neck radiotherapy.

Site

  • Anterior area (from 1.3 to 2.3 and from 3.3 to 4.3) and molar area
  • Previous guided bone regeneration
  • Location where there is not sufficient restorative space (mesio-distally <8mm for every restoration unit and <5mm from the bone crest to the antagonist)
  • Implant dehiscence of more than 2/3 of the implant.

Implant

  • Implants which cannot be restored with a screwed restoration
  • Implants which doesn't reach a manual implant stability
  • implants which after placement doesn't reach a favourable position according to the restoration.

Treatment and study plan

Test Group

Procedure

3.0mm diameter implant

Control Group

Procedure

4.0 diameter implant + guided bone regeneration

Primary outcomes

  1. Marginal bone level difference

    Time frame: The changes in MBL will be registered at 8 weeks, 6 months, 12 months, and 3 years.

    To assess the MBL, each radiograph must register the most coronal aspect of the bone crest (BC) at mesial and distal to the implant, the position of the implant shoulder (IS) and the first bone to implant contact (FBiC). The marginal bone crest level (MBL) will be measured by calculating the distance between BC and IS. MBL will be considered negative when position of BC is coronal to IS, positive when position BC is apical to IS.

Secondary outcomes

  1. Patient related outcomes

    Time frame: At 1, 2 and 12 weeks

    • Level of discomfort - at 1-, 2- and 12-weeks post-surgery (VAS scale): 0 - 4 (being 0 no discomfort and 4 very severe discomfort)

  2. Patient Related Outcomes

    Time frame: At 1, 2 and 12 weeks

    Willingness of undergoing same surgical procedure - at 1-, 2- and 12-weeks post-surgery (VAS scale): 0 - 4 (being 0 will never undergo this surgery again and 4 no problem to repeat this surgery)

  3. Patient Related Outcomes

    Time frame: At 7 days

    • Level of pain perceived - during first 7 days after surgery (VAS scale): 0-100 (being 0 no pain and 100 intolerable pain)

  4. Patient Related Outcomes

    Time frame: At 7 days

    Medication required: Number of ibuprofen tablets taken between the 2nd and the 7th day.

  5. Implant survival criteria:

    Time frame: 12 months

    Defined as the implant being still in function

  6. Implant success criteria:

    Time frame: 12 months

    Defined as absence of:

    • Persistent pain, foreign body sensation, and/or dysesthesia
    • Recurrent peri-implant infection with suppuration
    • Implant mobility
    • Continuous radiolucency around the implant
    • Clinical probing depth (CPD) ≥5 mm associated with bleeding/suppuration on probing (BoP/SoP).

  7. Prosthesis success criteria

    Time frame: 12 months

    • Absence of prosthesis (crown or abutment) mobility
    • Number of maintenance visits
    • Crown screw loosening
    • Abutment screw loosening
    • Implant fracture
    • Crown screw fracture
    • Abutment screw fracture
    • Crown chipping.

  8. Resonance frequency analysis

    Time frame: Implant surgery and after 12 months

    Resonance frequency analysis using Penguin ® will be measured immediately after implant placement, when taking implant impressions

  9. Level of keratinized tissue surrounding the implants

    Time frame: 12 months

    Level of keratinized tissue will be measured from the gingival margin of the restored implant to the mucogingival line using a periodontal millimetre probe.

  10. Peri-implant mucosal thickness using a millimetre probe

    Time frame: 12 months

  11. Presence of post-surgical complications

    Time frame: At 1, 2 and 12 weeks

    Defined as absence of:

    • Infection/suppuration
    • Wound dehiscence
    • Implant failure
    • Post-op oedema

  12. Presence of peri-implant health

    Time frame: At 12 weeks, 6 and 12 months

    Defined as:

    • Peri-implant probing depth (6 points).
    • Bleeding on probing (presence or absence).
    • Suppuration on probing (presence or absence).
    • Plaque index (presence or absence).

  13. Presence of prosthetic complications

    Time frame: At 6 and 12 months

    Defined as:

    • Number of maintenance visits
    • Crown screw loosening ("Yes" or "No")
    • Abutment screw loosening ("Yes" or "No")
    • Implant fracture ("Yes" or "No")
    • Crown screw fracture ("Yes" or "No")
    • Abutment screw fracture ("Yes" or "No")
    • Framework fracture ("Yes" or "No")
    • Crown ceramic chipping ("Yes" or "No")

Sponsors and collaborators

Lead sponsor

Universitat Internacional de Catalunya

Other

Collaborators

  • Klockner Implant System S.A.

Registry information

Official study title

Narrow Diameter Implants Versus Standard Diameter Implants With Simultaneous Bone Regeneration For The Treatment Of Atrophic Posterior Area

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Dec 13, 2023
Registry last updated
Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.